ANNOVIS BIO ANNOUNCES TWO PRESENTATIONS A... - Cure Parkinson's

Cure Parkinson's

25,345 members26,645 posts

ANNOVIS BIO ANNOUNCES TWO PRESENTATIONS AT THE AD/PD™ 2023 INTERNATIONAL CONFERENCE ON ALZHEIMER'S AND PARKINSON'S DISEASES

0 Replies

prnewswire.com/news-release...

Annovis will be making two presentations at the upcoming AD/PD™ 2023 International Conference on Alzheimer's and Parkinson's Disease, which is taking place from March 28 through April 1, 2023, in Gothenburg, Sweden.

The first presentation will discuss the Company's development plan for Parkinson's (PD) and Alzheimer's disease (AD), and the second presentation will show how mouse data fully predicts human outcome in improving function in AD and PD.

Read more about...

You may also like...

Annovis Bio Buntanetap Interim Analysis of the Parkinson's Clinical Study

https://www.prnewswire.com/news-releases/annovis-bio-announces-two-presentations-at-the-adpd-2023-in

Annovis Bio Announces Approval for EU Clinical Trial Sites for the Phase 3 Study of Buntanetap for the Treatment of Parkinson's Disease

EU sites yet. https://www.prnewswire.com/news-releases/annovis-bio-announces-approval-for-european-

Annovis Bio announced today the completion of patient enrollment for its phase III Parkinson’s Disease trial in a record nine months

https://www.prnewswire.com/news-releases/annovis-bio-announces-completion-of-phase-iii-parkinsons-di

AD/PD 2024: early diagnosis key for disease-modifying therapies in Parkinson’s

agnosis-remains-a-hurdle-for-disease-modifying-therapies-in-parkinsons/?cf-view

How much significant is this news?

Annovis Bio Inc. (ANVS) announces patients treated with ANVS401 for 25 days showed statistically...